Author(s):
Bitan Naik, Mahima Yadav, Vikas Kailashiya, Anu Singh, Anup Singh, Sandip Kumar
Email(s):
anusingh@bhu.ac.in
DOI:
10.52711/0974-360X.2024.00779
Address:
Bitan Naik1, Mahima Yadav2, Vikas Kailashiya3, Anu Singh4*, Anup Singh5, Sandip Kumar6
1MD Pathology, Assistant Professor, Department of Pathology, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh, India.
2MD Pathology, Assistant Professor, Department of Pathology, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh. India.
3MD Pathology, Assistant Professor, Department of Pathology, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh. India.
4MD Pathology, Assistant Professor, Department of Pathology, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh. India.
Address for communication- Department of Pathology, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, Uttar Pradesh. India.
5MD Medicine, Professor, Department of Geriatric Medicine, Institute of Medical Sciences (IMS), Bana
Published In:
Volume - 17,
Issue - 10,
Year - 2024
ABSTRACT:
Background: Role of anti-neutrophil cytoplasmic antibodies (ANCA) in pathogenesis of systemic lupus erythematous (SLE) and its association with clinical manifestations is not completely understood. Prevalence data of ANCA in SLE patients of Indian population is limited. Aims and Objectives: The aim of the present study is to measure the prevalence of ANCAs in SLE patients and study its association with clinical manifestations of SLE. Material and Methods: Total 92 patients of SLE cases were included in this prospective observational study. Demographic, clinical and laboratory data was collected in all patients. Serum levels of myeloperoxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA, antinuclear antibody (ANA), anti-dsDNA antibody and extractable nuclear antigen (ENA) antibodies were measured by enzyme immune assay methods. Serum Complement C3 and C4 estimation was done by nephelometer. Unpaired t test was used to find the significance difference in mean value between ANCA positive and ANCA negative group. Chi-square test was used to compare categorical data of two groups. Results: Nineteen cases (20.65%) showed ANCA positivity. Ten cases were positive for PR3-ANCA and seven cases were positive for MPO-ANCA. Two cases were detected with dual MPO and PR3-ANCA. Nephritis was significantly more common in ANCA positive SLE patients. Rest all of clinical manifestations, anti-dsDNA antibody positivity, ENAs antibodies positivity and reduction in complement level did not show any significant correlation with presence of ANCA antibody.
Conclusion: In contrast to results of earlier studies, PR3-ANCA was more prevalent in our study population. Renal system involvement was significantly high in ANCA positive SLE patients as compared to ANCA negative patients.
Cite this article:
Bitan Naik, Mahima Yadav, Vikas Kailashiya, Anu Singh, Anup Singh, Sandip Kumar. Prevalence of Antineutrophil cytoplasmic Antibodies in Systemic Lupus Erythematosus and its relevance with Clinical manifestations. Research Journal of Pharmacy and Technology. 2024; 17(10):5065-0. doi: 10.52711/0974-360X.2024.00779
Cite(Electronic):
Bitan Naik, Mahima Yadav, Vikas Kailashiya, Anu Singh, Anup Singh, Sandip Kumar. Prevalence of Antineutrophil cytoplasmic Antibodies in Systemic Lupus Erythematosus and its relevance with Clinical manifestations. Research Journal of Pharmacy and Technology. 2024; 17(10):5065-0. doi: 10.52711/0974-360X.2024.00779 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-10-64
REFERENCES:
1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006; 368(9533):.404-418.
2. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020; 6(1):71.
3. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651-658.
4. Galeazzi M, Morozzi G, Sebastiani GD, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998;16(5):541-546.
5. Nishiya K, Chikazawa H, Nishimura S, Hisakawa N, Hashimoto K. Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Clin Rheumatol. 1997;16(1):70-75.
6. Su F, Xiao W, Yang P, Chen Q, Sun X, Li T. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. An Bras Dermatol. 2017;92(4):466-469.
7. Fauzi AR, Kong NC, Chua MK, Jeyabalan V, Idris MN, Azizah R. Antibodies in systemic lupus antineutrophil cytoplasmic erythematosus: prevalence, disease activity correlations and organ system associations. Med J Malaysia. 2004;59(3):372-377.
8. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum. 1995;38(5):633-637.
9. Manolova I, Dancheva M, Halacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int. 2001;20(5):197-204.
10. Mahde SM, Shamma IA, Mousawy KM, Sheikhly A, Laith A. The role of Antineutrophilic Cytoplasmic Antibodies in Patients with Systemic Lupus Erythematosus. J Fac Med Baghdad. 2005;47(4):392-393.
11. Pradhan VD, Badakere SS, Bichile LS, Almeida AF. Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. J Assoc Physicians India. 2004;52:533-537.
12. Wang S, Shang J, Xiao J, Zhao Z. Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. Ren Fail. 2020;42(1):244-254.
13. Paul BJ, Fassaludeen M, Nandakumar, Razia MV. Clinical profile of systemic Lupus Erythematosus in northern Kerala. J Indian Rheumatol Assoc. 2003;11:94-97.
14. Saigal R, Kansal A, Mittal M, Singh Y, Maharia HR, Juneja M. Clinical profile of systemic lupus erythematosus patients at a tertiary care centre in Western India. J Indian Acad Clin Med. 2011;13:27-32.
15. Malaviya AN, Misra R, Banerjee S, et al. Systemic lupus erythematosus in North Indian Asians. A prospective analysis of clinical and immunological features. Rheumatol Int. 1986;6(3):97-101.
16. Talukdar D, Gogoi AP, Doley D, Marak RR, Kakati S, Pradhan V et al. The Clinical and Immunological profiles of Systemic Lupus Erythematosus Patients from Assam, North-East India. Indian J Rheumatol. 2020;15:181-186.
17. Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol. 2000;20(1):57-63.
18. Pan HF, Fang XH, Wu GC, et al. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation. 2008;31(4):260-265.
19. Pauzner R, Urowitz M, Gladman D, Gough J. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol. 1994;21(9):1670-1673.
20. Faria AC, Barcellos KS, Andrade LE. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol. 2005;32(7):1267-1272.
21. Jallouli M, Frigui M, Hmida MB, Marzouk S, Kaddour N, Bahloul Z. Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients. Saudi J Kidney Dis Transpl. 2008;19(6):1001-1008